JOP20210187A1 - تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p) - Google Patents

تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)

Info

Publication number
JOP20210187A1
JOP20210187A1 JOP/2021/0187A JOP20210187A JOP20210187A1 JO P20210187 A1 JOP20210187 A1 JO P20210187A1 JO P20210187 A JOP20210187 A JO P20210187A JO P20210187 A1 JOP20210187 A1 JO P20210187A1
Authority
JO
Jordan
Prior art keywords
sphingosine
phosphate
receptor modulators
compositions
amino
Prior art date
Application number
JOP/2021/0187A
Other languages
English (en)
Inventor
Ruegger Colleen
Ambuhl Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032615&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20210187(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20210187A1 publication Critical patent/JOP20210187A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)

Abstract

يتعلق الاختراع المطروح بتركيبات ثابتة تتضمن معدلات مستقبل سفينجوزين 1 فوسفات (S1P)، مناسبة للاستعمال في صورة جرعة. و تكون معدلات مستقبل S1P عبارة عن منشطات نموذجية للسفينجوزين مثل مشتقات 2- مستبدل 2- أمينو andndash; بروبان andndash; 3.1- ديول أو 2- أمينو andndash; بروبانول مثل مركب يضم مجموعة ذات الصيغة Y.
JOP/2021/0187A 2007-10-12 2021-07-08 تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p) JOP20210187A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97948207P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
JOP20210187A1 true JOP20210187A1 (ar) 2023-01-30

Family

ID=40032615

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2008/0436A JOP20080436B1 (ar) 2007-10-12 2008-10-09 تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)
JOP/2021/0187A JOP20210187A1 (ar) 2007-10-12 2021-07-08 تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2008/0436A JOP20080436B1 (ar) 2007-10-12 2008-10-09 تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)

Country Status (33)

Country Link
US (6) US8673918B2 (ar)
EP (7) EP2465492B1 (ar)
JP (2) JP6034000B2 (ar)
KR (3) KR101600098B1 (ar)
CN (1) CN101820916A (ar)
AR (1) AR068986A1 (ar)
AU (1) AU2008310846C1 (ar)
BR (1) BRPI0818161B8 (ar)
CA (2) CA2925175A1 (ar)
CL (1) CL2008003003A1 (ar)
CO (1) CO6270342A2 (ar)
DK (1) DK2952177T3 (ar)
EC (1) ECSP10010169A (ar)
ES (2) ES2864671T3 (ar)
HK (1) HK1213768A1 (ar)
HR (1) HRP20150838T1 (ar)
HU (2) HUE027696T2 (ar)
IL (3) IL204514B (ar)
JO (2) JOP20080436B1 (ar)
MA (1) MA31799B1 (ar)
MX (1) MX337152B (ar)
MY (1) MY159358A (ar)
NZ (1) NZ600355A (ar)
PE (2) PE20130309A1 (ar)
PL (2) PL2952177T3 (ar)
PT (2) PT2465492E (ar)
RU (1) RU2010118457A (ar)
SG (2) SG187458A1 (ar)
SI (2) SI2465492T1 (ar)
TN (1) TN2010000136A1 (ar)
TW (1) TW200927142A (ar)
WO (1) WO2009048993A2 (ar)
ZA (1) ZA201001819B (ar)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
SG193803A1 (en) * 2008-08-18 2013-10-30 Novartis Ag Compounds for the treatment of peripheral neuropathies
AR074826A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p
ES2538413T3 (es) 2008-12-22 2015-06-19 Novartis Ag Régimen de dosificación de un agonista del receptor S1P
WO2011131369A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod in the form of a solid solution
WO2011131370A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Melt-granulated fingolimod
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) * 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
SG10201602279PA (en) * 2011-10-21 2016-04-28 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2996681B1 (en) * 2013-05-13 2019-12-18 Synthon B.V. Pharmaceutical composition comprising fingolimod
WO2015015254A1 (en) 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015155711A1 (en) * 2014-04-10 2015-10-15 Novartis Ag Immunosuppressant formulation
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CN113559075A (zh) * 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
CN107530342A (zh) * 2015-04-28 2018-01-02 安斯泰来制药有限公司 口服给药用医药组合物
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
MX2018004021A (es) * 2015-10-02 2018-09-11 Mylan Inc Formulaciones estables de fingolimod.
SG11201809299QA (en) * 2016-04-22 2018-11-29 Incyte Corp Formulations of an lsd1 inhibitor
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
EP3813789A1 (en) 2018-06-28 2021-05-05 Arx, LLC Dispensing method for producing dissolvable unit dose film constructs
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
KR20220142376A (ko) * 2021-04-14 2022-10-21 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
CZ285953B6 (cs) 1995-12-28 1999-12-15 Yoshitomi Pharmaceutical Industries, Ltd. Vnější přípravek pro topické podání
EP2030614A1 (en) 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
KR100551931B1 (ko) 1997-04-04 2006-02-16 미츠비시 웰파마 가부시키가이샤 2-아미노프로판-1,3-디올 화합물, 이것의 의약으로서의 용도 및 합성 중간체
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1431284B1 (en) 2001-09-27 2007-11-21 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
AU2003264430B2 (en) 2002-09-19 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
BRPI0407658A (pt) 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
DE122011100047I1 (de) * 2003-04-08 2011-12-15 Mitsubishi Tanabe Pharma Corp Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol.
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr) 2003-05-06 2005-06-24 Actis Ets Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
WO2005002559A2 (en) 2003-06-24 2005-01-13 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
AU2004268052B2 (en) 2003-08-28 2009-11-19 Novartis Ag Aminopropanol derivatives
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2006102611A2 (en) 2005-03-24 2006-09-28 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia
CN1891212B (zh) 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
EP3103448B1 (en) * 2006-09-26 2019-07-03 Novartis Ag Pharmaceutical compositions comprising an s1p modulator

Also Published As

Publication number Publication date
AU2008310846A1 (en) 2009-04-16
PL2952177T3 (pl) 2021-07-19
US20150165046A1 (en) 2015-06-18
JP6034000B2 (ja) 2016-11-30
TW200927142A (en) 2009-07-01
EP2465492B1 (en) 2015-07-01
EP2653154A1 (en) 2013-10-23
EP2209493A2 (en) 2010-07-28
AU2008310846C1 (en) 2022-10-06
JP2011500583A (ja) 2011-01-06
KR101600098B1 (ko) 2016-03-04
US20100267675A1 (en) 2010-10-21
CN101820916A (zh) 2010-09-01
EP3733161A1 (en) 2020-11-04
HRP20150838T1 (hr) 2015-11-06
PE20090799A1 (es) 2009-07-20
PE20130309A1 (es) 2013-03-30
IL277999A (en) 2020-11-30
EP2465492A1 (en) 2012-06-20
MA31799B1 (ar) 2010-10-01
SI2465492T1 (sl) 2015-12-31
IL255737A (en) 2018-01-31
KR20100091179A (ko) 2010-08-18
MX337152B (es) 2016-02-15
EP3733162A1 (en) 2020-11-04
PL2465492T3 (pl) 2015-11-30
PT2952177T (pt) 2021-04-26
SG187458A1 (en) 2013-02-28
MY159358A (en) 2016-12-30
AR068986A1 (es) 2009-12-23
JOP20080436B1 (ar) 2023-03-28
CO6270342A2 (es) 2011-04-20
IL255737B (en) 2020-10-29
TN2010000136A1 (en) 2011-09-26
US9399066B2 (en) 2016-07-26
ECSP10010169A (es) 2010-06-29
RU2010118457A (ru) 2011-11-20
KR20160025633A (ko) 2016-03-08
ZA201001819B (en) 2010-12-29
US20160296481A1 (en) 2016-10-13
SG10201800085XA (en) 2018-02-27
CA2925175A1 (en) 2009-04-16
HUE027696T2 (en) 2016-10-28
DK2952177T3 (da) 2021-04-26
KR101710845B1 (ko) 2017-02-27
RU2016138157A3 (ar) 2020-02-10
MX2010003925A (es) 2010-05-05
EP3120833A1 (en) 2017-01-25
US20140142192A1 (en) 2014-05-22
ES2545361T3 (es) 2015-09-10
AU2008310846B2 (en) 2012-06-21
JP2015091822A (ja) 2015-05-14
SI2952177T1 (sl) 2021-07-30
KR20170021904A (ko) 2017-02-28
WO2009048993A3 (en) 2010-05-06
CA2699788C (en) 2016-06-14
NZ600355A (en) 2013-02-22
WO2009048993A2 (en) 2009-04-16
CA2699788A1 (en) 2009-04-16
HUE053835T2 (hu) 2021-07-28
BRPI0818161A2 (pt) 2017-05-16
IL204514B (en) 2018-01-31
US20170151195A1 (en) 2017-06-01
EP2952177A1 (en) 2015-12-09
US8673918B2 (en) 2014-03-18
ES2864671T3 (es) 2021-10-14
HK1213768A1 (zh) 2016-07-15
BRPI0818161B8 (pt) 2021-05-25
BRPI0818161B1 (pt) 2020-12-22
RU2016138157A (ru) 2018-12-13
CL2008003003A1 (es) 2009-05-15
PT2465492E (pt) 2015-10-15
EP2952177B1 (en) 2021-01-20
US20170368001A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
JOP20210187A1 (ar) تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)
MX2019012750A (es) Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
SV2010003737A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
ECSP088854A (es) Moduladores bencimidazolicos de vr1
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
PH12013500365A1 (en) Anti-infective agents and uses thereof
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
MX2010002902A (es) Pirimidinas anti-infecciosas y usos de las mismas.
EA201200239A1 (ru) Бициклические арильные аналоги сфингозин 1-фосфата
MX348471B (es) Composiciones farmaceuticas que comprenden un modulador de s1p.
PH12014502462A1 (en) Complement pathway modulators and uses thereof
TN2011000585A1 (en) Lxr modulators
UA98623C2 (ru) Соединения диосметина, способ их получения и фармацевтическая композиция, которая их содержит
CA2818986A1 (en) Indole derivatives as modulators of s1p receptors
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
WO2012071212A3 (en) Novel phosphonic acids as s1p receptor modulators
MA32834B1 (ar) 3 أمينوسيكلوبينتانيكاربوكساميد يعمل كمغير مستقبلات الشيموكين
BR112012023039A2 (pt) pirimidina substituída como um antagonista de receptor prostaglandina d2
EA201301150A1 (ru) Новые пиперидинилмонокарбоновые кислоты в качестве агонистов s1p1 рецепторов
MX2009012683A (es) Benzamidas utiles como moduladores del receptor s1p.
CA2818993A1 (en) Modulators of s1p receptors
TH103571A (th) องค์ประกอบซึ่งประกอบด้วยตัวปรับสฟิงโกชีน 1 ฟอสเฟด (s1p) รีเซพเตอร์
UA86549C2 (en) 1-(aminomethyl)-2,2,2-trifluoroethyl phosphonic acid